High Denial RiskRevenue at Risk: $542K–$1.1M (est)Effective Jan 1, 2025 · CA SB 1120

New State AI-in-UM Law Reshapes Payer Obligations in Your Market

California SB 1120 (Physicians Make Decisions Act, Chapter 879, Statutes of 2024) amends Health & Safety Code §1367.01 to prohibit health care service plans and disability insurers from issuing medical necessity denials, delays, or modifications based solely on AI or algorithmic tools. Final determinations must be made by a licensed physician or qualified health care professional, based on the enrollee's individual clinical circumstances — not solely on group datasets. Sponsored by the California Medical Association and a national precedent.

Published by the PAULA Intelligence TeamReviewed by a board-certified Physician Advisor
Affected Payers
  • · Medicare Advantage (CA-operating)
  • · Commercial (Knox-Keene)
  • · Medi-Cal Managed Care
Service Lines
  • · Prior Auth
  • · Medical Necessity
  • · Observation
  • · Inpatient UR
01 — Signal

Why PAULA flagged this

Multi-state compliance variance: CLIP scoring must branch by member state for human-review mandates, AI-disclosure obligations, and denial-rationale standards. SB 1120 sets the national template — additional state legislatures are tracking and citing it. For California-enrolled members, every AI-assisted denial without documented licensed-physician final review is a per se reversal candidate.

Recommended Action — Within 14 Days

Map SB 1120 requirements to your contracted California payers and update your appeal workflow. Stand up a California-member flag in your PA automation stack so every denial from a Knox-Keene or Medi-Cal MCO payer triggers a mandatory request for reviewer name, NPI, licensure, and individualized clinical basis before acceptance.

Locked · Full Brief

Scenarios, defenses, P2P scripts, executive lenses, and payer impact unlock with any briefing tier.

02 — Full Analysis

What SB 1120 requires of California UM workflows

03 — Denial Scenarios PAULA is Watching

Three high-probability denial patterns

PAULA inference based on payer behavior patterns and the source rule's structure — not directly quoted in the regulatory text. Verify against current payer policy before citing in an appeal.

Scenario · 01

AI-Only Prior Auth Denial Without Documented Physician Sign-Off

Payer Argument

(Inferred) A California Knox-Keene-licensed MA or commercial payer issues a PA denial for an inpatient admission or elective procedure citing InterQual or MCG criteria outputs but lacks any documented licensed physician attestation of final review. Payer may claim internal workflow satisfies SB 1120 but cannot produce evidence of human reviewer identity, credentials, or individualized clinical rationale.

Defense

Upon receipt of any PA denial from a California-regulated plan effective Jan 1, 2025, UR team must request in writing the name, NPI, and licensure of the reviewing clinician. If the denial cites only algorithmic or criteria-tool output without named physician attestation, flag as SB 1120 non-compliant and escalate to physician advisor. File a concurrent DMHC complaint (Knox-Keene) or CDI complaint (disability insurers) if human review cannot be documented. Preserve all denial correspondence for audit.

P2P Framing

'Per California Health & Safety Code §1367.01 as amended by SB 1120, effective Jan 1, 2025, a final determination on medical necessity may not be made solely by an AI or algorithmic tool — a licensed physician or qualified health care professional must make the final call. I am requesting confirmation of the reviewing clinician's name, licensure, and the individualized clinical basis for this denial specific to this enrollee's clinical history.'

Scenario · 02

Inpatient-to-Observation Downgrade Driven by Payer AI Tool

Payer Argument

(Inferred) A California commercial payer or Medi-Cal managed care plan issues a concurrent or retrospective downgrade from inpatient to observation, citing AI-assisted review of MCG thresholds. The payer asserts attending documentation did not meet population-level inpatient benchmarks embedded in the tool, without demonstrating that the enrollee's individual clinical circumstances were evaluated by a licensed physician.

Defense

Ensure every California-enrolled inpatient admission includes an explicit attending attestation: 'Inpatient admission medically necessary based on [specific individual clinical findings] which exceed observation-level management given [specific risk factors] — not based solely on population criteria.' Concurrent-review nurse must document payer reviewer name and credentials on each contact. Any downgrade must trigger physician advisor review of SB 1120 compliance before acceptance.

P2P Framing

'Under H&S §1367.01 as amended by SB 1120, any modification of services based on medical necessity must reflect the enrollee's specific medical and clinical history and individual clinical circumstances — not solely group datasets. I am requesting confirmation that a licensed physician made this downgrade based on a review of this patient's individual record, and I would like to discuss the specific clinical basis for observation status being sufficient.'

Scenario · 03

Behavioral Health Denial — Population Benchmarks vs. Individual History

Payer Argument

(Inferred) A California Knox-Keene behavioral health managed care plan denies continued inpatient psychiatric or residential treatment, citing standardized algorithmic assessment (e.g., LOCUS/CALOCUS scores processed through AI-assisted UR) and aggregate population discharge benchmarks rather than documented individualized review of this enrollee's psychiatric history, current acuity, and treatment response.

Defense

Implement a BH-specific UR template requiring the attending psychiatrist to document individual risk factors, specific barriers to step-down, treatment response to date, and explicit statement that level-of-care change would pose individualized clinical risk. On any BH denial from a CA plan, request reviewer name, NPI, and licensure — if not a licensed psychiatrist or doctoral-level psychologist, flag for SB 1120 'qualified health care professional' challenge. Submit DMHC complaint if individualized human review cannot be documented.

P2P Framing

'This continued-stay determination involves a psychiatric presentation with individualized clinical factors including [specific symptoms, risk factors, treatment barriers] in the submitted record. SB 1120 requires AI tool determinations to be based on this enrollee's specific clinical history and individual circumstances — not solely on group datasets. I am requesting a P2P with the licensed clinician who made this determination and documentation that this was not an AI-only determination.'

04 — Decision Layer

Three executive lenses

Physician Advisor

SB 1120 legally reinforces your role: you — a licensed physician or qualified health care professional — must make the final medical necessity determination; you cannot delegate that to an AI tool or algorithm, even as a preliminary screen. Anchor every P2P in the enrollee's individual clinical circumstances and name SB 1120's group-dataset-only prohibition directly when the payer reviewer cannot articulate how the AI output was validated against individualized data. Request the payer reviewer's specialty credentials to confirm they meet the 'qualified health care professional' standard for the clinical question at issue.

CFO / Revenue Cycle

SB 1120 creates material, immediate revenue exposure for CA-enrolled patients beginning Jan 1, 2025. Calculate California PA volume, identify the subset processed through AI-assisted UR, and stress-test what percentage of denials lack documented human-reviewer credentials — each is a reversal candidate. The critical tech gap is in your CLIP/PA workflow: without a California-specific branch flagging human-review documentation and SB 1120 disclosure compliance, you are generating a denial inventory that will be systematically overturned. Build automated flags for IMR deadlines, which run concurrently with internal appeals — missed IMR windows are unrecoverable revenue losses.

Compliance & Legal

SB 1120 is the highest-priority AI governance trigger in the CLAIR layer for CA-enrolled plans as of Jan 1, 2025. CLAIR must treat any AI/algorithm/software tool used in UM as subject to the full compliance framework: human-final-determination audit trails, individualized-data validation logs, non-discrimination monitoring, periodic performance reviews, and data-use-limitation controls. AI vendor contracts must include audit-cooperation clauses giving DMHC and DHCS access to performance data — vendor confidentiality provisions that conflict with SB 1120's audit authority are unenforceable against regulators. SB 1120's national precedent status makes the CA-compliance template the recommended proactive multi-state AI governance posture.

05 — Denial Playbook

Appeal phrasing, levers & citations

06 — Payer Impact

Projected payer behavior

PAULA watch item — projected payer behavior under this rule. Verify against current payer medical policy or provider bulletin.

Commercial (Knox-Keene, CA)
High

Primary target of the law. Demand written documentation of the human reviewer identity on every denial; escalate any denial lacking this to compliance and legal.

Medicare Advantage (CA-operating)
Medium

Denial volume may decrease due to required human review, but appeals leverage increases significantly if plans fail to comply. Document non-compliant AI-only denials for appeal.

Medi-Cal Managed Care
High

DHCS audit authority is explicit. Treat MCO denials lacking individualized clinical review as per se SB 1120 risk events for fair-hearing reversal.

Self-Funded ERISA (in CA)
Low–Medium

SB 1120 does not reach ERISA self-funded plans, but document AI-only denial patterns for potential future federal regulatory leverage.

Underwriter Read · Pathway Risk Artifact

How this brief lands across the affected payment pathways

Composed from PAULA's internal Underwriter / CFO intelligence corpus. Each pathway is scored on a five-signal frame — loss frequency, loss severity, signal quality, regulatory volatility, and denial-risk index.

Pathway 6 · MA / commercial VBC

Medicare Advantage / Commercial — Shared Savings, Capitation, and Value-Based Contracts

Severe · 4.7Viability · High

The strongest funding model for UM/CDI AI specifically. Shared savings, capitation, and risk-bearing contracts directly reward denial avoidance, status-determination accuracy, and reduced unnecessary utilization. Self-funds when AI moves the shared-savings number.

5
Loss Freq
5
Loss Sev
4
Signal Qual
5
Reg Volatility
5
Denial Risk
Top scenario · AI-Driven Inpatient Admission Challenged as Non-FAVES-Compliant$7.2M revenue at risk
Pathway 7 · CMMI APM

CMMI Alternative Payment Models — EOM, ACO REACH, and ACCESS

High · 3.5Viability · Emerging

CMMI APMs create financial structures enabling — and in some cases requiring — AI-enabled care delivery, but vary by model. ACO REACH and EOM offer the clearest AI economics today; broader applicability depends on model evolution under the current administration.

3
Loss Freq
4
Loss Sev
2
Signal Qual
4
Reg Volatility
3
Denial Risk
Top scenario · AI-Driven Inpatient Admission Challenged as Non-FAVES-Compliant$7.2M revenue at risk
Source intelligence held internally · Not distributed as a standalone PDF
Operationalize this brief

Choose your briefing tier.

One-time purchase · Delivered as a downloadable executive PDF with citations and CLIP-ready operational templates.

Sources: California SB 1120 (Chapter 879, Statutes of 2024) amending Health & Safety Code §1367.01 · DMHC and DHCS audit authority. Source Confidence: MEDIUM — Statutory text available; verify against current DMHC guidance and payer policy before formal use.
PAULA · Clinefficiency Pro — Real-time decision intelligence for UM, denial risk, and regulatory change.